


IFW



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
3612/US

In Re Application Of: Stephen P. Arneric

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/727,717	December 4, 2003	TBA	26 648	1632	6897

Title: A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Postcard, Form 1449, Information Disclosure Statement, Copy of (19) Ref.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**


Signature

Dated: November 2, 2004

James Michael Warner
Registration No. 45,199
Customer No. 26 648

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

11/02/04

(Date)


Signature of Person Mailing Correspondence

Matthew J. Bell

Typed or Printed Name of Person Mailing Correspondence

cc:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of)
Stephen P. Arneric) Attorney Docket No. 3612/US
)
Serial No.10/727,717) Group Art Unit: 1632
)
Filed: December 4, 2003) Examiner: TBA

For A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS
DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF
DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND CYCLOOXYGENASE-
2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF

November 2, 2004

Assistant Commissioner of Patents
Alexandria, VA 22313


SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,


James M. Warner, Reg. No. 45,199
Attorney for Applicants
(314) 274-3642 (St. Louis)

Pharmacia Corporation of Pfizer
P.O. Box 1027
St. Louis, MO
63006



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3612/US	APPLICATION NO.: 10/727,717
	INVENTOR: Stephen P. Americ	
	Filed: December 4, 2004	Group: 1632

U.S. PATENT DOCUMENTS

Examiner Initial		Documet Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,434,178	07/18/95	Talley, et al.	514	406	11/30/93
	2	5,476,944	12/19/95	Partis, et al.	514	357	05/19/94
	3	5,859,257	01/12/99	Talley, et al.	548	247	08/14/96
	4	5,643,933	07/01/97	Talley, et al.	514	372	06/02/95
	5	5,932,598	08/03/99	Talley, et al.	514	341	01/12/98
	6	6,156,781	12/05/00	Talley, et al.	514	406	11/24/99
	7	6,110,960	08/29/00	Janusz, et al.	514	432	01/06/97
	8	6,180,651	01/30/01	Nicolai, et al.	514	336	01/30/01
	9	5,521,207	05/28/96	Graneto	514	406	04/06/94
	10	5,760,068	02/09/95	Lopez	435	43	02/09/95
	11	2001/0029257 A1	10/11/01	Murdock	514	220	10/11/01
	12	6,180,651	01/30/01	Nicolai, et al.	514	336	01/09/01
	13	4,535,186	08/13/85	Husbands, et al.	564	336	10/26/83
	14	4,761,501	08/02/88	Husbands, et al.	564	167	05/22/85
	15	6,290,986 B1	09/18/01	Murdock, et al.	424	449	06/29/98
	16	6,229,010 B1	05/08/01	Crocker, et al.	544	132	12/09/99
	17	6,096,742 B1	08/01/00	Crocker, et al.	514	241	12/15/98
	18	6,191,133 B1	02/20/01	Coppen	514	249	06/24/98
	19	6,184,222 B1	02/06/01	Heiligenstein	514	239	09/17/98
	20	6,066,643	05/23/00	Perry	514	269	10/09/98
	21	6,028,070	02/22/00	Heiligenstein	514	238.8	09/17/98
	22	6,274,171 B2	08/14/01	Sherman, et al.	488	629	01/20/00
	23	4,314,081	02/02/82	Molloy, et al.	564	347	01/10/74
	24	6,066,043	05/23/00	Knisely, et al.	454	285	12/08/97
	25	5,023,269	06/11/91	Robertson, et al.	514	498	03/27/90
	26	5,362,886	11/08/94	Berglund, et al.	549	75	10/12/93
	27	6,245,802	06/12/01	Iyegar, et al.	514	438	11/11/99

FOREIGN PATENT DOCUMENTS

Examiner Initial		Documet Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	27	WO 00/24719	05/04/00	Black, et al.	237	14	10/27/99
	28	WO 96/12485	05/02/96	Heligenstein, et al.	31	38	10/20/94
	29	WO 00/28980	05/25/00	Iyegar, et al.	31	00	11/18/95

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3612/US	APPLICATION NO.: 10/727,717
	INVENTOR: Stephen P. Americ.	
	Filed: December 4, 2003	Group: 1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	30	Needleman, P. et al., <i>J. Rheumatol.</i> , 24 Suppl.49:6-8 (1997).
	31	Fu, J. Y., et al., <i>J. Biol. Chem.</i> , 265(28):16737-40 (1990).
	32	Samad, T.A. et al. <i>Nature</i> , 410(6827):471-5 (2001).
	33	Buttgereit, F. et al., <i>Am. J. Med.</i> , 110(3 Suppl. 1):13-9 (2001).
	34	Osiri, M. et al, <i>Arthristis Care Res.</i> , 12 (5):351-62 (1999).
	35	Buttar, N.S. et al., <i>Mayo Clin. Proc.</i> , 75(10):1027-38 (2000).
	36	Wollheim, F.A. <i>Current Opin. Rheumatol.</i> , 13:193-201 (2001)
	37	Hillson, J. L. et al., <i>Expert Opin. Pharmacother.</i> , 1(5):1053-66 (2000).
	38	Jamali, F., <i>J. Pharm. Pharm. Sci.</i> , 4(1):1-6 (2001).
	39	Saag, K. et al., <i>Arch Fam. Med.</i> , 9(10):1124-34 (2000).
	40	Goodman & Goodman's, <i>The Pharmacological Basis of Therapeutics</i> , Ninth Edition (1996), Appendix II, pp. 1707-1711.
	41	Winter, et al., <i>Proc. Soc. Exp. Biol. Med</i> , 111, 544 (1962).
	42	NSAIDS, in <i>Non-steroidal Anti-Inflammatory Drugs</i> , (J. Lombardino, ed. 1985).
	43	Hargreaves, et al., <i>Pain</i> , 32, 77 (1988).
	44	J. Stuart, <i>Annual Rev. Immunol.</i> , 2, 199 (1984).
	45	P. Wooley, et al., <i>Trans. Proc.</i> , 15 180 (1983).
	46	R. Jonsson, <i>J. Immunol. Methods</i> , 88, 109 (1986).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)